Pediatrix Medical Group (MD) Q2 2024 earnings summary

Executive summary

• Q2 2024 net loss was $153 million ($1.84 per share), driven by significant non-cash impairments and restructuring costs, while Adjusted EPS was $0.34 and Adjusted EBITDA was $57.9 million, slightly down year-over-year.

• Net revenue for Q2 2024 was $504.3 million, up 0.7% year-over-year, supported by a strong payer mix, stable patient volumes, and growth in hospital-based and maternal-fetal medicine services, offset by declines in NICU days and office-based pediatric urgent care.

• Portfolio restructuring is underway, with exits from most office-based practices except maternal-fetal medicine, and divestiture of primary and urgent care clinics, aiming to focus on core hospital-based services.

• A one-time payer settlement favorably impacted Adjusted EBITDA by $3 million.

• Leadership changes include the appointment of a new CFO and Chief Administrative Officer, effective Q3 2024.

Financial highlights

• Six-month net revenue was $999.4 million, up 0.8% year-over-year, with same-unit net revenue up 2.9%.

• Operating cash flow for Q2 was $109 million, up from $93 million year-over-year.

• Cash and cash equivalents at June 30, 2024, were $19.4 million, down from $73.3 million at year-end 2023.

• Net debt declined to roughly $600 million, at or below 3x leverage based on full-year Adjusted EBITDA outlook.

• DSO improved to 49.5 days at quarter-end, down from 52 days sequentially.

Outlook and guidance

• Full-year 2024 Adjusted EBITDA guidance remains at $200 million to $220 million.

• Portfolio restructuring is expected to add approximately $30 million in annualized Adjusted EBITDA upon completion, with the full impact realized in 2025.

• Annual capital expenditures are projected to decline to $16 million–$20 million post-restructuring.

• Management expects available funds to be sufficient for obligations for at least the next 12 months.